american society of clinical oncology virtual meeting

Investment bank analysts permeate scientific conferences like ASCO, which makes them crucial venues for smaller At ASCO this year, Trillium expects to present details from an early-stage clinical trial of its experimental treatment TTI-622 in relapsed lymphoma patients. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trialPrimary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancerComparison of the phase 3 trials in secondary cytoreductive surgery.Further insight into the activity of PARP inhibitors (PARPi) and PARPi combinationsWe use cookies to help provide and enhance our service and tailor content and ads. Stock Market

April 30, 2020 ... will be available on the meeting … He genuinely enjoys cutting through the complexity to help everyday investors make better decisions. Let's conquer your financial goals together...faster. Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California Los Angeles, Los Angeles, CA, United States of AmericaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America

adavosertib, camrelizumab, and mirvetuximab) or approaches (HDC-aSCR) across all gynecologic malignancies. Mirza and colleagues (#6050) reported no impact on efficacy of this individualized starting dose, with a hazard ratio for PFS with maintenance niraparib of 0.59 (95% CI 0.46–0.76) in patients enrolled to PRIMA who received the fixed starting dose of 300 mg daily regardless of weight or platelets, and a hazard ratio of 0.69 (95% CI 0.48–0.98) for those patients who received the individualized starting dose [Activity from the combination of the folate-receptor alpha-targeting antibody-drug conjugate mirvetuximab soravtansine in combination with bevacizumab in tumors demonstrating medium or high FRα membrane staining was reported (#6004) [Final results from the KEYNOTE100 study of pembrolizumab monotherapy in relapsed ovarian cancer were also reported (#6005) [A single arm Phase 2 trial reported on the activity of the Wee1 inhibitor adavosertib in uterine serous carcinomas (#6009) [Lheureux and colleagues reported results from a trial comparing the combination of nivolumab and cabozantinib to nivolumab monotherapy in recurrent endometrial cancer (#6010) [An analysis of disease free and disease specific survival in patients with early stage cervical cancer who underwent sentinel lymph node biopsy versus bilateral pelvic lymphadenectomy was reported from two prospective trials (SENTICOL I and II) (#6006) [A phase 3 study evaluating the role of adjuvant therapy after radical hysterectomy in cervical cancer (STARS trial) was also presented (#6007) [In an ancillary data analysis of GOG 49, 92, and 141 of early stage cervical cancer patients, Levinson et al. Below we present some of the highlights from this year's meeting.This year, two prospective trials evaluating secondary cytoreductive surgery (SCS) were presented; Lastly, another study of SCS presented was a randomized phase 2 trial of SCS with or without carboplatin hyperthermic intraperitoneal chemotherapy (HIPEC) in women with recurrent platinum sensitive ovarian cancer (#6016) [This year, SOLO2 (#6002), a randomized Phase 3 trial of olaparib maintenance therapy in women with relapsed platinum-sensitive BRCA-mutated ovarian cancer following response to platinum-based therapy, became the first report of mature OS data from a Phase 3 setting [The primary analysis of NRG-GY004, a Phase 3 trial comparing the combination of cediranib and olaparib or olaparib monotherapy to platinum-based chemotherapy in relapsed platinum-sensitive ovarian cancer was also presented (#6003) [Two Phase 2 trials reported this ASCO also provided additional insight into PARPi activity as monotherapy or in combination.

ASCO’s growing roster of cutting-edge journals serves readers as the most credible, authoritative, peer-reviewed resources for significant clinical oncology research and research that informs the delivery of efficient, high-quality cancer care across the globe. Personal Finance One major effort is to mandate that insurance carriers, including Medicare, cover the routine costs associated with clinical trial participation. Cory is a long-term minded analyst focused on the Healthcare Sector.

(TMFang4apples) By continuing you agree to the